If you missed the run-up in stocks such as VVUS, ARNA, and MDVN over the last twelve months now is the time to invest a few dollars in Mannkind (MNKD) before it triples in price.
Mannkind offers substantial upside considering the potential worldwide market for its diabetes drug, Afrezza, which is currently in phase three trials will be over $200 billion dollars by 2017. The company also has a number of promising drugs in development for the treatment of various cancers. Mannkind has already partnered on one of them which could provide the company with a minimum of $145,000,000. The next twelve months should be a continual uptrend for the share price as it moves towards an F.D.A. decision.
With the short interest in Mannkind shares currently in the 30,000,000 range if the company announces that its billionaire C.E.O., Al Mann, will fund the company through approval or if the company has obtained a loan on corporate assets (i.s. the Danbury facility) so that another secondary will not be necessary the resultant short squeeze could move the share price to the $8.00 range or higher.
Mr. Mann did receive an estimated $300,000,000 from the recent sale of Stellar Micro Electronics which he has available to fund Mannkind until the F.D.A.'s decision if he choses to do so.
One important factor to consider is that the company is currently in partnership talks with several "big pharma" companies in regards to marketing Afrezza in the United States. The company has also stated that it will utilize its European partner to file for approval in the E.U.